Benzinga
Benzinga
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Benzinga
lunedì, ottobre 26
Notizie dall’Italia
Azioni
Indici
Obbligazioni
ETF
Economia
Generale
Notizie USA
Azioni
Indici
Utili
Notizie Economiche
Mercati di previsione
Mercati privati
Altri Mercati
Dicono gli Analisti
Trading
Comunicati stampa
Notizie internazionali
Europa
Asia
Criptovalute
Notizie
Altcoin
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Finanza personale
Investire in criptovalute
Investire in azioni
Forex
Dyne Therapeutics Inc
DYN
NASDAQ
Watchlist
Get Report
Trade with Public
Get Report
Trade with Public
$15.62
-0.15
-0.95%
Ult. Agg.: Oct 23, 4:00 PM
Get Report
Panoramica
Notizie
Previsioni utili
Eventi
Obiettivi di prezzo
Dati finanziari
Sentiment
Azionariato
Confronta
Rapporto azionario
Dyne Therapeutics Financials
Dyne Therapeutics (DYN) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
PRO
Dyne Therapeutics Q2 EPS $(1.08) Misses $(0.75) Estimate
Dyne Therapeutics (NASDAQ:DYN) reported quarterly losses of $(1.08) per share which missed the analyst consensus estimate of $(0.75) by 44 percent. This is a 11.34 percent decrease over losses of $(0.97) per share from
Benzinga Newsdesk
PRO
Dyne Therapeutics Q1 EPS $(0.73) Beats $(0.78) Estimate
Dyne Therapeutics (NASDAQ:DYN) reported quarterly losses of $(0.73) per share which beat the analyst consensus estimate of $(0.78) by 6.41 percent. This is a 30.48 percent increase over losses of $(1.05) per share from
Benzinga Newsdesk
PRO
Dyne Therapeutics Q4 EPS $(0.76) Beats $(0.79) Estimate
Dyne Therapeutics (NASDAQ:DYN) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of $(0.79) by 3.18 percent. This is a 13.64 percent increase over losses of $(0.88) per share from
Benzinga Newsdesk
Sarepta CEO To Jump Ship After 'Tumultuous' Year
Sarepta stock drops after a wider loss, Elevidys sales fall 33%, and CEO retirement plans add fresh uncertainty for investors.
Vandana Singh
PRO
Dyne Therapeutics Q3 EPS $(0.76) Beats $(0.85) Estimate
Dyne Therapeutics (NASDAQ:DYN) reported quarterly losses of $(0.76) per share which beat the analyst consensus estimate of $(0.85) by 11.01 percent. This is a 20.83 percent increase over losses of $(0.96) per share from
Benzinga Newsdesk
These Analysts Lower Their Forecasts On Dyne Therapeutics Following Q2 Loss
Avi Kapoor
